<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01765088</url>
  </required_header>
  <id_info>
    <org_study_id>CSNO2012001</org_study_id>
    <nct_id>NCT01765088</nct_id>
  </id_info>
  <brief_title>A Phase III Trial on Adjuvant Temozolomide With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas</brief_title>
  <official_title>A Phase III Trial on Adjuvant Standard Temozolomide Chemotherapy With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to help determine whether the addition of
      Interferon-alpha(α-IFN),which were determined sensitized the activity of Temozolomide(TMZ) in
      vivo and vitro, when given along with temozolomide during the monthly cycles that follow
      radiation, is able to delay tumor growth, shrink tumors, or impact how long people with newly
      diagnosed high-grade glioma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is being conducted to help determine whether the addition of
      Interferon-alpha(α-IFN),which were determined sensitized the activity of Temozolomide(TMZ) in
      vivo and vitro, when given along with temozolomide during the monthly cycles that follow
      radiation, is able to delay tumor growth, shrink tumors, or impact how long people with newly
      diagnosed high-grade glioma. Four weeks after radiotherapy, newly diagnosed WHO III-IV glioma
      patients will be randomised into two groups: TMZ group or TMZ+ α-IFN groups.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Over-all survival</measure>
    <time_frame>5-year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>5-year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Anaplastic Oligoastrocytoma</condition>
  <condition>Anaplastic Astrocytoma</condition>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>temozolomide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Four weeks after radiotherapy, patients will be received 6 cycle of temozolomide (150 mg/m^2 daily on Days 1-5 of each 28 day study cycle and 200 mg/m^2 daily of subsequent cycles)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>temozolomide +α-IFN</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Four weeks after radiotherapy, patients will be received 6 cycle of temozolomide plus α-IFN α-IFN：3mIU (3million) Day1,3,5 of each 28 day TMZ：150 mg/m^2 daily on Days 2-6 of each 28 day study cycle and 200 mg/m^2 daily of subsequent cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>dosed at 200 mg/m2 (150 mg/m2 for the first cycle) daily for 5 consecutive days, repeated every 28 days</description>
    <arm_group_label>temozolomide</arm_group_label>
    <arm_group_label>temozolomide +α-IFN</arm_group_label>
    <other_name>Temodar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>α-IFN</intervention_name>
    <description>3mIU (3million) D1，3，5</description>
    <arm_group_label>temozolomide +α-IFN</arm_group_label>
    <other_name>INTRONA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 18 years to 75 years

          -  newly diagnosed WHO III-IV glioma after operation and radiotherapy

          -  Karnofsky Performance Score ≥ 60

          -  Adequate bone marrow, liver and renal function

          -  Ability of subject to understand character and individual consequences of the clinical
             trial

          -  Written informed consent

          -  anticipating survival ≥2 months

        Exclusion Criteria:

          -  Refusal to participate the study

          -  Known hypersensitivity or contraindication to temozolomide

          -  Incompletely radiation

          -  Pregnant or lactating females

          -  Malignant tumor other than brain tumor

          -  Contraindicated for MRI examination

          -  Unable to comply with the follow-up studies of this trial

          -  Purulent and chronic infected wounds

          -  Uncontrolled psychotic disorders or epilepsy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zhong-ping CHEN, MD, PhD</last_name>
    <phone>+86-20-87343310</phone>
    <email>chenzhp@sysucc.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cheng-cheng GUO, MD, PhD</last_name>
    <phone>+86-20-87343309</phone>
    <email>guochch@sysucc.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhong-ping Chen, MD,PhD</last_name>
      <phone>+86-20-87343310</phone>
      <email>chenzhp@sysucc.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Cheng-cheng Guo, MD,PhD</last_name>
      <phone>+86-20-87343656</phone>
      <email>guochch@sysucc.org.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Zhong-ping Chen, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2013</study_first_submitted>
  <study_first_submitted_qc>January 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2013</study_first_posted>
  <last_update_submitted>February 21, 2018</last_update_submitted>
  <last_update_submitted_qc>February 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Zhongping Chen</investigator_full_name>
    <investigator_title>Professor and Chair, Department of Neurosurgery</investigator_title>
  </responsible_party>
  <keyword>High-grade glioma</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>Temozolomide</keyword>
  <keyword>Interferon-alpha</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Astrocytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

